

Amer M Zeidan Mbbs, Mhs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/965556/publications.pdf>

Version: 2024-02-01

221
papers

4,705
citations

117571

34
h-index

149623

56
g-index

221
all docs

221
docs citations

221
times ranked

5230
citing authors

#	ARTICLE	IF	CITATIONS
1	Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patientsâ€™ Perspectives on Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e185-e198.	0.2	9
2	Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 762-764.	0.6	1
3	A review of FLT3 inhibitors in acute myeloid leukemia. <i>Blood Reviews</i> , 2022, 52, 100905.	2.8	50
4	Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. <i>Blood</i> , 2022, 139, 624-629.	0.6	12
5	Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 43-50.	1.0	1
6	Myeloid-derived suppressor cells: a grey eminence in the AML tumor microenvironment?. <i>Expert Review of Anticancer Therapy</i> , 2022, , 1-3.	1.1	2
7	Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. <i>Annals of Hematology</i> , 2022, 101, 557-569.	0.8	44
8	A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 523-534.	0.2	3
9	The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. <i>Leukemia and Lymphoma</i> , 2022, 63, 1651-1659.	0.6	5
10	Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <i>Leukemia</i> , 2022, 36, 1432-1435.	3.3	5
11	Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1766-1770.	0.6	4
12	In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. <i>Leukemia</i> , 2022, 36, 1313-1323.	3.3	11
13	Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 670-679.	0.2	2
14	Under-use of Hypomethylating Agents in Patients With Higher-risk Myelodysplastic Syndrome in the United States: A Large Population-based Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e206-e211.	0.2	14
15	Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e248-e254.	0.2	5
16	TIM-3 pathway dysregulation and targeting in cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 523-534.	1.1	54
17	High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1195-1202.	0.6	5
18	Interferon alpha therapy in essential thrombocythemia and polycythemia veraâ€™a systematic review and meta-analysis. <i>Leukemia</i> , 2021, 35, 1643-1660.	3.3	29

#	ARTICLE	IF	CITATIONS
19	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2021, 113, 92-99.	0.7	13
20	Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. <i>Blood Reviews</i> , 2021, 45, 100709.	2.8	24
21	Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. <i>Cancer Management and Research</i> , 2021, Volume 13, 645-657.	0.9	5
22	Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 994-1002.	2.5	18
23	Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?. <i>Expert Review of Hematology</i> , 2021, 14, 199-210.	1.0	5
24	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. <i>Hemato</i> , 2021, 2, 79-88.	0.2	0
25	Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101245.	0.7	8
26	Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e185-e193.	2.2	271
27	Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). <i>Cancers</i> , 2021, 13, 1610.	1.7	17
28	Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-10.	0.6	0
29	Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 276-285.	1.2	1
30	The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 989-1002.	1.1	2
31	BiTEs, DARTS, BiKEs and TriKEs – Are Antibody Based Therapies Changing the Future Treatment of AML?. <i>Life</i> , 2021, 11, 465.	1.1	21
32	Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia. <i>Oncotarget</i> , 2021, 12, 1314-1317.	0.8	1
33	The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. <i>Blood Reviews</i> , 2021, 48, 100806.	2.8	14
34	Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes. <i>Transfusion</i> , 2021, 61, 2830-2836.	0.8	10
35	Management of the Older Patient with Myelodysplastic Syndrome. <i>Drugs and Aging</i> , 2021, 38, 751-767.	1.3	9
36	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2021, 62, 3394-3401.	0.6	17

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 4686-4690.	2.5	4
38	Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation—A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 997.e1-997.e11.	0.6	20
39	Cost-effectiveness of gilteritinib for relapsed/refractory FLT3 ^{mut+} acute myeloid leukemia. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1469-1481.	0.5	3
40	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 873.e1-873.e13.	0.6	9
41	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. <i>Lancet Oncology</i> , 2021, 22, 1597-1608.	5.1	90
42	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110434.	1.1	3
43	Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period. <i>Blood</i> , 2021, 138, 4092-4092.	0.6	0
44	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2021, 138, 2592-2592.	0.6	0
45	Immune and Epigenetic Landscape of TP53-mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS). <i>Blood</i> , 2021, 138, 3371-3371.	0.6	3
46	Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States. <i>Blood</i> , 2021, 138, 277-277.	0.6	4
47	Outcomes for Patients with Late-Stage Mutant-IDH2 (m-IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial. <i>Blood</i> , 2021, 138, 1243-1243.	0.6	9
48	Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2021, 138, 1522-1522.	0.6	3
49	Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis. <i>Blood</i> , 2021, 138, 182-182.	0.6	0
50	Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. <i>Haematologica</i> , 2020, 105, 102-111.	1.7	31
51	Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. <i>Leukemia and Lymphoma</i> , 2020, 61, 397-408.	0.6	19
52	The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 40, 100639.	2.8	15
53	Lifestyle factors and risk of myeloproliferative neoplasms in the NIH AARP diet and health study. <i>International Journal of Cancer</i> , 2020, 147, 948-957.	2.3	9
54	Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101132.	0.7	5

#	ARTICLE	IF	CITATIONS
55	The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 43, 100650.	2.8	17
56	Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. <i>Leukemia and Lymphoma</i> , 2020, 61, 1178-1187.	0.6	15
57	Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. <i>Cells</i> , 2020, 9, 2310.	1.8	37
58	No child with a transfusion-dependent haemoglobinopathy left unchelated: are we there yet?. <i>Lancet Haematology</i> , 2020, 7, e429-e430.	2.2	0
59	Complete, yet partial: the benefits of complete response with partial haematological recovery as an endpoint in acute myeloid leukaemia clinical trials. <i>Lancet Haematology</i> , 2020, 7, 853-856.	2.2	2
60	Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes. <i>Cancer</i> , 2020, 126, 4664-4667.	2.0	0
61	Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta-analysis. <i>Transfusion</i> , 2020, 60, 2360-2369.	0.8	32
62	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	2.2	56
63	Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?. <i>Expert Review of Hematology</i> , 2020, 13, 1131-1142.	1.0	8
64	Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2343-2350.	1.1	1
65	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. <i>Leukemia and Lymphoma</i> , 2020, 61, 3287-3305.	0.6	2
66	A complex karyotype and a genetic mutation in acute myeloid leukaemia. <i>Lancet</i> , 2020, 396, 2018.	6.3	0
67	Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101222.	0.7	9
68	Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. <i>Leukemia and Lymphoma</i> , 2020, 61, 2180-2190.	0.6	24
69	Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?. <i>Leukemia and Lymphoma</i> , 2020, 61, 2295-2312.	0.6	7
70	Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e712-e723.	0.2	12
71	Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2020, 13, 447-460.	1.0	2
72	Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption. <i>International Journal of Cancer</i> , 2020, 146, 3523-3523.	2.3	1

#	ARTICLE	IF	CITATIONS
73	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	3.3	54
74	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	0.6	15
75	Evolving therapies for lower-risk myelodysplastic syndromes. <i>Annals of Hematology</i> , 2020, 99, 677-692.	0.8	16
76	Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. <i>Leukemia and Lymphoma</i> , 2020, 61, 1455-1464.	0.6	4
77	Special considerations in the management of patients with myelodysplastic syndrome / myeloproliferative neoplasm overlap syndromes during the <scp>SARSâ€CoV</scp>â€2 pandemic. <i>American Journal of Hematology</i> , 2020, 95, E203-E208.	2.0	10
78	Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. <i>Expert Review of Hematology</i> , 2020, 13, 489-499.	1.0	24
79	Isolated trisomy 11 in patients with acute myeloid leukemia â€ is the prognosis not as grim as previously thought?*. <i>Leukemia and Lymphoma</i> , 2020, 61, 2254-2257.	0.6	1
80	Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. <i>Blood Reviews</i> , 2020, 42, 100706.	2.8	54
81	A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6132-6140.	3.2	45
82	Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial. <i>Blood</i> , 2020, 136, 7-7.	0.6	1
83	Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study. <i>Blood</i> , 2020, 136, 13-15.	0.6	7
84	Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia. <i>Current Cancer Drug Targets</i> , 2020, 20, 473-489.	0.8	4
85	Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
86	Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia. <i>Blood</i> , 2020, 136, 21-22.	0.6	1
87	Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (E18171). <i>Blood</i> , 2020, 136, 1-1.	0.6	3
88	Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 237-240.	0.8	2
89	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 246-249.	0.6	0
90	Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. <i>Cancer</i> , 2019, 125, 4241-4251.	2.0	28

#	ARTICLE	IF	CITATIONS
91	Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 717-729.	1.1	12
92	One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant. <i>Expert Review of Hematology</i> , 2019, 12, 575-578.	1.0	4
93	RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 3181-3187.	0.6	9
94	Healthcare expenses for treatment of acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 641-650.	1.0	14
95	Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. <i>Leukemia and Lymphoma</i> , 2019, 60, 2584-2587.	0.6	1
96	Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. <i>Blood Reviews</i> , 2019, 36, 70-87.	2.8	484
97	Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 393-404.	1.1	26
98	Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?. <i>Cancer</i> , 2019, 125, 1410-1413.	2.0	7
99	Transforming growth factor (TGF)- β 2 pathway as a therapeutic target in lower risk myelodysplastic syndromes. <i>Leukemia</i> , 2019, 33, 1303-1312.	3.3	43
100	Getting personal with myelodysplastic syndromes: is now the right time?. <i>Expert Review of Hematology</i> , 2019, 12, 215-224.	1.0	9
101	Epigenetic therapy combinations in acute myeloid leukemia: what are the options?. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071881669.	1.1	71
102	Myeloid disorders after autoimmune disease. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 74-88.	0.7	19
103	<p>Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10777-10790.	0.9	32
104	Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes. <i>Annals of Hematology</i> , 2019, 98, 339-350.	0.8	26
105	Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 2019, 60, 1354-1369.	0.6	23
106	Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2019, 60, 2050-2055.	0.6	4
107	Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?. <i>Blood Reviews</i> , 2019, 34, 67-83.	2.8	80
108	Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. <i>Blood Reviews</i> , 2019, 34, 1-15.	2.8	117

#	ARTICLE	IF	CITATIONS
109	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degradator, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study. <i>Blood</i> , 2019, 134, 232-232.	0.6	17
110	Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , 2019, 134, 2547-2547.	0.6	5
111	Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). <i>Blood</i> , 2019, 134, 4748-4748.	0.6	1
112	Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 211-219.	2.3	6
113	Improved JAK Inhibition in Myelofibrosis—The Long Road Ahead. <i>JAMA Oncology</i> , 2018, 4, 659.	3.4	1
114	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1754-1758.	2.0	6
115	Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?. <i>Leukemia and Lymphoma</i> , 2018, 59, 2015-2017.	0.6	5
116	Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. <i>Blood</i> , 2018, 131, 818-821.	0.6	45
117	To chelate or not to chelate in MDS: That is the question!. <i>Blood Reviews</i> , 2018, 32, 368-377.	2.8	25
118	Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1030-1032.	0.6	4
119	The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. <i>Blood Advances</i> , 2018, 2, 2681-2690.	2.5	13
120	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 1765-1772.	2.5	100
121	Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. <i>Cancer</i> , 2018, 124, 4211-4220.	2.0	9
122	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 923-932.	2.5	114
123	Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. <i>Journal of Blood Medicine</i> , 2018, Volume 9, 67-74.	0.7	18
124	Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts. <i>European Journal of Haematology</i> , 2018, 101, 711-720.	1.1	70
125	Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?. <i>Blood Cancer Journal</i> , 2018, 8, 55.	2.8	26
126	Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. <i>Expert Review of Hematology</i> , 2018, 11, 715-726.	1.0	14

#	ARTICLE	IF	CITATIONS
127	More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematology, 2018, 18, 4.	2.6	8
128	The genetic and molecular pathogenesis of myelodysplastic syndromes. European Journal of Haematology, 2018, 101, 260-271.	1.1	58
129	Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. Annals of Hematology, 2018, 97, 2333-2343.	0.8	6
130	Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies. Annals of Hematology, 2018, 97, 2245-2248.	0.8	2
131	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 1-1.	0.6	57
132	Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey. Blood, 2018, 132, 1825-1825.	0.6	2
133	Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort. Blood, 2018, 132, 1428-1428.	0.6	1
134	Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. Blood, 2018, 132, 3580-3580.	0.6	2
135	Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort. Blood, 2018, 132, 4040-4040.	0.6	4
136	Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?. Cancer, 2017, 123, 911-914.	2.0	16
137	Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome. Annals of Hematology, 2017, 96, 1037-1039.	0.8	6
138	Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Review of Hematology, 2017, 10, 345-364.	1.0	12
139	Management of myelofibrosis: JAK inhibition and beyond. Expert Review of Hematology, 2017, 10, 459-477.	1.0	11
140	Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. Cancer, 2017, 123, 3754-3762.	2.0	18
141	Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer, 2017, 123, 3763-3771.	2.0	25
142	Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016. Leukemia Research, 2017, 53, 8-12.	0.4	1
143	Therapy-related myelodysplastic syndromes, or are they?. Blood Reviews, 2017, 31, 119-128.	2.8	28
144	The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. Blood Reviews, 2017, 31, 370-388.	2.8	29

#	ARTICLE	IF	CITATIONS
145	Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 117, 57-66.	2.0	10
146	A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. <i>Cancer</i> , 2017, 123, 3662-3672.	2.0	39
147	Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?. <i>Targeted Oncology</i> , 2017, 12, 413-447.	1.7	19
148	The importance of erythroblast enumeration in myeloid neoplasia. <i>Annals of Hematology</i> , 2017, 96, 329-330.	0.8	7
149	Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study. <i>Prostate</i> , 2017, 77, 437-445.	1.2	24
150	Selecting initial treatment of acute myeloid leukaemia in older adults. <i>Blood Reviews</i> , 2017, 31, 43-62.	2.8	74
151	A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. <i>British Journal of Haematology</i> , 2017, 176, 241-247.	1.2	23
152	Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. <i>Leukemia and Lymphoma</i> , 2017, 58, 982-985.	0.6	16
153	Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1660.	1.8	33
154	Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. <i>Journal of Clinical Oncology</i> , 2017, 35, 3417-3424.	0.8	61
155	A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies. <i>Blood</i> , 2017, 130, 640-640.	0.6	3
156	A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes (MDS) after hypomethylating agent (HMAs) failure.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7010-7010.	0.8	1
157	Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. <i>PLoS ONE</i> , 2017, 12, e0184747.	1.1	9
158	Risk stratification in therapy-related myelodysplastic syndromes. <i>Oncotarget</i> , 2017, 8, 80103-80104.	0.8	4
159	Physician volume and discontinuation of rituximab during lymphoma treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6593-6593.	0.8	0
160	Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7057-7057.	0.8	0
161	Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States. <i>Blood</i> , 2017, 130, 675-675.	0.6	0
162	Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. <i>Cancer</i> , 2016, 122, 1598-1607.	2.0	19

#	ARTICLE	IF	CITATIONS
163	Chronic myelomonocytic leukemia: Are we finally solving the identity crisis?. <i>Blood Reviews</i> , 2016, 30, 381-388.	2.8	3
164	Emerging biological therapies for the treatment of myelodysplastic syndromes. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 283-300.	1.0	15
165	Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2016, 175, 829-840.	1.2	59
166	Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2016, 95, 1895-1898.	0.8	2
167	Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. <i>Annals of Hematology</i> , 2016, 95, 1197-1200.	0.8	28
168	New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. <i>Expert Review of Hematology</i> , 2016, 9, 377-388.	1.0	16
169	Economic burden associated with acute myeloid leukemia treatment. <i>Expert Review of Hematology</i> , 2016, 9, 79-89.	1.0	35
170	The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. <i>Blood Reviews</i> , 2016, 30, 1-10.	2.8	32
171	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. <i>Blood</i> , 2016, 128, 1063-1063.	0.6	5
172	Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. <i>Blood</i> , 2016, 128, 1188-1188.	0.6	1
173	Epigenetics in Cancer: A Hematological Perspective. <i>PLoS Genetics</i> , 2016, 12, e1006193.	1.5	77
174	The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions. <i>Current Diabetes Reviews</i> , 2016, 12, 231-239.	0.6	8
175	Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. <i>World Journal of Stem Cells</i> , 2016, 8, 316.	1.3	17
176	Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2016, 128, 2820-2820.	0.6	0
177	Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. <i>Blood</i> , 2016, 128, 394-394.	0.6	0
178	Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D. <i>Journal of Oncology Practice</i> , 2015, 11, e190-e198.	2.5	4
179	Myelodysplastic syndromes: from conducting clinical trials of novel therapies to evaluating real-life effectiveness of existing therapies. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 215-217.	0.7	0
180	Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. <i>American Journal of Hematology</i> , 2015, 90, 1036-1040.	2.0	23

#	ARTICLE	IF	CITATIONS
181	Case Report of a Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-3.	0.2	4
182	Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 766-770.e4.	0.2	13
183	Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. <i>Oncologist</i> , 2015, 20, 1069-1076.	1.9	20
184	Leukaemic vasculitis with myelodysplastic syndrome. <i>Lancet</i> , The, 2015, 386, 501-502.	6.3	7
185	Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions. <i>Seminars in Hematology</i> , 2015, 52, 172-183.	1.8	54
186	Current state of prognostication and risk stratification in myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2015, 22, 146-154.	1.2	25
187	Real-Life Experience of a Brief Arsenic Trioxide-Based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 292-297.	0.2	9
188	The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1019-1036.	1.1	17
189	Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 327-340.	0.6	33
190	Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 705-710.	0.2	36
191	Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial. <i>Blood</i> , 2015, 126, 1666-1666.	0.6	12
192	Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study. <i>Blood</i> , 2015, 126, 1676-1676.	0.6	0
193	Results of a Phase 2 Trial of High Dose Lenalidomide Monotherapy in Patients with Relapsed/Refractory Higher-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia with Trilineage Dysplasia. <i>Blood</i> , 2015, 126, 2901-2901.	0.6	0
194	Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). <i>Blood</i> , 2015, 126, 3285-3285.	0.6	1
195	Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US). <i>Blood</i> , 2015, 126, 873-873.	0.6	5
196	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. <i>Blood</i> , 2015, 126, 1138-1138.	0.6	4
197	Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey. <i>Blood</i> , 2015, 126, 4455-4455.	0.6	0
198	Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC). <i>Blood</i> , 2015, 126, 2889-2889.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. <i>Journal of Blood Medicine</i> , 2014, 6, 1.	0.7	14
200	Spontaneous splenic rupture during induction chemotherapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 209-212.	0.6	8
201	Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?. <i>Expert Review of Hematology</i> , 2014, 7, 191-194.	1.0	6
202	Comparison of the prognostic utility of the revised International Prognostic Scoring System and the <sc>F</sc>rench Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2014, 166, 352-359.	1.2	31
203	Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2014, 21, 123-130.	1.2	41
204	HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 314-318.	2.0	103
205	Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised <sc>IPSS</sc>. <i>British Journal of Haematology</i> , 2014, 167, 62-68.	1.2	27
206	New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach. <i>Clinical Cancer Research</i> , 2014, 20, 4985-4993.	3.2	14
207	Venous thromboembolism prophylaxis in hematopoietic stem cell transplantation patients: an international web-based survey of healthcare providers. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 524-526.	1.0	4
208	Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. <i>Gynecologic Oncology</i> , 2014, 135, 163-171.	0.6	112
209	Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?. <i>Expert Review of Hematology</i> , 2013, 6, 251-254.	1.0	18
210	Myelodysplastic syndromes: What do hospitalists need to know?. <i>Journal of Hospital Medicine</i> , 2013, 8, 351-357.	0.7	21
211	Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?. <i>Expert Review of Hematology</i> , 2013, 6, 539-542.	1.0	5
212	Current therapy of myelodysplastic syndromes. <i>Blood Reviews</i> , 2013, 27, 243-259.	2.8	75
213	There's™s Risk, and Then There's™s RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 351-360.	1.2	37
214	Iron chelation therapy in myelodysplastic syndromes: where do we stand?. <i>Expert Review of Hematology</i> , 2013, 6, 397-410.	1.0	46
215	Prognostication in Myelodysplastic Syndromes: Beyond the International Prognostic Scoring System (IPSS). <i>American Journal of Medicine</i> , 2013, 126, e25.	0.6	26
216	Successful treatment of severe refractory hepatic graft-versus-host disease by cadaveric liver transplant. <i>Leukemia and Lymphoma</i> , 2013, 54, 2756-2759.	0.6	4

#	ARTICLE	IF	CITATIONS
217	Lenalidomide performance in the real world. <i>Cancer</i> , 2013, 119, 3870-3878.	2.0	37
218	The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy). <i>Blood</i> , 2013, 122, 4629-4629.	0.6	1
219	Validation Of a Brief Arsenic Trioxide (ATO)-Based Consolidation Chemotherapy In The Upfront Management Of Acute Promyelocytic Leukemia (APL): Less Anthracycline Exposure and Faster Completion Of Consolidation Therapy With Equivalent Survival. <i>Blood</i> , 2013, 122, 3963-3963.	0.6	1
220	The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza). <i>Blood</i> , 2013, 122, 2771-2771.	0.6	0
221	Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. <i>British Journal of Haematology</i> , 2012, 158, 198-207.	1.2	7